Boston wins second round of stent patent skirmish with Medtronic:
This article was originally published in Clinica
Executive Summary
Shares in Boston Scientific ended last week on the rise after a US court of appeals upheld a previous ruling that found the Natick, Massachusetts company not guilty of infringing patents owned by its arch rival Medtronic. The latter had filed the appeal following a trial in January 2005 when a district court judge ruled that Boston's Taxus Express, Express and NIR stents did not infringe four of Medtronic's patents as claimed by the Minneapolis, Minnesota firm (see Clinica No 1140, p 13). The news led to a 3% rise in Boston's share price, closing at $20.47 last Friday (May 26) while Medtronic's shares dipped 1% to close at $50.26.
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.